AusperBio

AusperBio is committed to the research and development of innovative drugs and vaccines for the treatment and prevention of chronic hepatitis B and other major infectious diseases. Currently, AusperBio's three innovative pipelines—hepatitis B curative small nucleic acid drug platform, hepatitis B therapeutic vaccine platform, and a collaboratively developed intranasal antibody platform—have all entered the clinical trial application stage. Small nucleic acid drugs refer to oligonucleotide molecules including small interfering nucleic acids (siRNA), antisense oligonucleotides (ASO), microRNAs (miRNA), and nucleic acid aptamers. Composed of nucleotides, small nucleic acid drugs represent an entirely new category of pharmaceuticals distinct from small molecule drugs and antibody drugs. The primary types of small nucleic acid drugs are siRNA drugs and ASO drugs, both of which primarily target mRNA in the cytoplasm. By recognizing and inhibiting target mRNA through base-pair complementarity, they regulate protein expression to achieve therapeutic effects.